Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Calidi is a clinical-stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses (RedTail, SuperNova, and NeuroNova platforms). The company has no approved products and generates no product revenue.
Capital Structure Event: On August 4, 2025, the company effected a 1-for-12 reverse stock split. All share and per-share data in this filing are retrospectively adjusted.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss (Attributable to Common Stockholders) | $(10.82) million | $(21.52) million | $(19.72) million |
| Net Loss (GAAP) | $(5.18) million | $(16.00) million | $(18.06) million |
| Operating Expenses | $(5.05) million | $(15.77) million | $(17.75) million |
| Cash and Restricted Cash | $10.59 million | $10.59 million | $2.12 million |
| Total Debt (Net Carrying Value) | $1.07 million | $1.07 million | $3.82 million |
| Accumulated Deficit | $(137.57) million | $(137.57) million | $(117.62) million |
Note: The significant increase in Net Loss attributable to common stockholders in Q3 2025 includes a non-cash "deemed dividend on warrants" of $5.67 million.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 11% year-over-year for the nine months ended September 30, 2025 ($15.77M vs. $17.75M). This reduction was driven primarily by a 21% decrease in General and Administrative (G&A) expenses due to lower legal fees, insurance costs, and salaries.
- Debt Reduction: Total debt obligations decreased significantly from $3.82 million at December 31, 2024, to $1.07 million at September 30, 2025. The company repaid $2.0 million in related party term notes and a $0.2 million bridge loan during the period.
- Financing Activity: The company raised approximately $20.3 million in gross proceeds during the nine months ended September 30, 2025, through public offerings, registered direct offerings, and a warrant inducement offer.
- Warrant Liability: The fair value of warrant liabilities increased to $0.20 million (from $0.13 million at year-end 2024), resulting in a net loss impact from changes in fair value.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of issuance. The company has an accumulated deficit of $137.6 million and expects to continue incurring losses. Continued operations depend on raising additional capital through equity or debt financing.
- Subsequent Events:
- Nova Cell Spin-off: On October 27, 2025, the company sold its 75% ownership interest in its subsidiary, Nova Cell, for a purchase price of $6.0 million (partially satisfied by debt cancellation). Nova Cell is no longer a consolidated subsidiary.
- ATM Offering: Between October 1 and November 10, 2025, the company issued 261,409 shares for $0.4 million in net proceeds.
- Legal Proceedings: The company is involved in litigation regarding former executives (defamation, constructive discharge, and breach of fiduciary duty) and a securities fraud complaint filed in October 2024. Management does not currently expect these matters to have a material adverse effect, though outcomes are uncertain.
- Executive Changes: The company executed separation agreements with the former CEO, former Chief Legal Officer, and former President of Medical and Scientific Affairs during the quarter, incurring severance obligations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $10.6 million cash balance against the burn rate, given the explicit "substantial doubt" going concern warning.
- Debt Obligations: Confirm the status of the remaining $0.6 million promissory note and $0.4 million accrued interest on related party term notes.
- Warrant Overhang: Assess the dilution risk from 5.03 million outstanding warrants, many with exercise prices significantly above current trading levels.
- Nova Cell Transaction: Review the terms of the $6.0 million sale of Nova Cell, specifically the deferred consideration and royalty obligations.
- Legal Exposure: Monitor the status of the securities fraud lawsuit and employment-related litigation for potential settlement costs.